













A thesis submitted to Johns Hopkins University in conformity with 






















Hepatitis C virus (HCV) infects millions of people worldwide with the majority of 
infections becoming chronic. Chronic infection can result in severe morbidity and 
mortality. Although recently developed therapies are increasingly more effective at 
clearing virus, many hurdles prevent universal access to treatment. Therefore, a vaccine 
to prevent progression to chronic disease is an appropriate public health solution. 
Interestingly, about 25% of initial HCV infections are spontaneously resolved without 
treatment. However, the immune correlates of protection are not fully elucidated. 
Individuals who clear the initial infection can become reinfected, but upon reinfection 
tend to have attenuated viral kinetics, suggesting a role for the adaptive immune 
response.  
Clearance of a reinfection models a successful immune response upon re-exposure. In 
this analysis, we examine the protective role of CD8 T cells during HCV reinfections 
using a prospective cohort study of individuals at high-risk of acquiring HCV in 
Baltimore, Maryland. The cellular immune response during reinfection was characterized 
by assessing breadth, specificity, and magnitude of anti-viral cytokines produced upon 
recognition of HCV epitopes. We then phenotyped HCV-specific CD8 T cells to examine 
the dynamics of activation, exhaustion, maturation, and memory of the immune response 
during reinfection.  
The results suggest an association between reinfection events and enhanced magnitude 







dampened upon reinfection but are capable of becoming activated and vary in T cell 
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Public health implications  
HCV epidemiology 
Hepatitis C virus (HCV) infects 170 million people worldwide, with an increase in global 
prevalence of anti-HCV antibodies from roughly 122 million to 185 million persons 
between 1990 and 2005 (Hanafiah 2013). In the United States, an estimated 3.6 million 
or 1.3% of the general population have anti-HCV antibodies, though only 2.7 million or 
1.0% of the population have chronic HCV infection (Denniston 2014).  However, 
evaluation of the burden of disease due to HCV is conservative because acute illness is 
generally clinically mild thus typically unrecognized and infrequently diagnosed, and 
high at-risk populations such as homeless and incarcerated persons are not included in 
most estimates (Westbrook 2014, Denniston 2014). Rates of HCV seroprevalence are 
dramatically higher in correctional facilities compared to the general population, with 
seroprevalence estimates ranging from 27-30% of male and 38-49% of female inmates 
compared to 1.3% of the general United States population (Baillargeon 2003, Macalino 
2004). Therefore, expanded prevalence studies that include underrepresented high-risk 
groups not contained in previous studies such as the homeless, incarcerated people, 
veterans, health care workers, and those on long-term dialysis estimated that 
approximately 2.0% of the United States population have HCV infection (Chak 2011). 
Prevalence of chronic HCV infection in the United States is greatest in those born 
between 1945 and 1965, representing 81% of chronic HCV infection (Denniston 2014). 
However, incidence of HCV infection increased in every age group in 2012 compared to 







1.73 cases per 100,000 people (CDC 2014). Rising incidence indicative of an emerging 
epidemic is present in people aged 24 or younger, of white race, residing in suburban 
areas, and who used oral prescription-type opioids prior to using heroin (Klevens 2012, 
Pollini 2013, Valdiserri 2014). While injection drug use is the most common risk factor 
for acquiring HCV, because transmission occurs primarily through percutaneous 
exposure to blood, other methods of acquiring HCV include a history of receiving a 
blood product transfusion prior to 1992, receiving body tattoos in a non-professional 
parlor, and, though infrequently, in men who have sex with men (Williams 2011, Tohme 
2010, Tohme 2012). The prevalence of HCV antibodies is between 75% and 90% among 
people who inject drugs (Spach 2014).  
Mortality and morbidity associated with HCV 
Substantial morbidity and mortality from HCV occur due to chronic infection. In Western 
countries, chronic HCV infection is the leading cause of end-stage liver disease, 
hepatocellular carcinoma, and liver related death, and is the leading indication for liver 
transplant (Westbrook 2014). An estimated 27% of cirrhosis and 25% of hepatocellular 
carcinoma is attributable to HCV infection globally (Perz 2006). Moreover, HCV 
infection accounted for 366,000 deaths in 2002 worldwide, with an estimated 211,000 
from cirrhosis and 155,000 from liver cancer (Perz 2006). In the United States, deaths 
due to HCV surpassed deaths due to HIV in 2007 when 15,106 HCV-related deaths were 









Treatments and prevention 
Although there is no current vaccine to prevent HCV infection, efficacy, as gauged by 
viral clearance and tolerability of medications, has improved with recent therapeutic 
developments. The initial regimen of interferon alfa monotherapy had a viral clearance 
rate of less than 10%, but this has shifted to more than 70% with the current therapies 
(Liang 2013). Interferon alfa induces interferon-stimulated genes that inhibit HCV 
replication by inducing antiviral functions, but therapies have evolved to be interferon-
free, to improve tolerability, and to decrease duration of therapy (Liang 2013, Kohli 
2014). Although direct-acting antivirals target HCV replication and processing at various 
steps in the life cycle, there are drawbacks to such targeted action, such as genotype-
specific efficacy. For example, boceprevir and telaprevir, NS3/NS4A serine protease 
inhibitors that prevent proteolytic processing of the HCV polyprotein, have narrow 
coverage beyond genotype 1 infection (Liang 2013, Kohli 2014). Additionally, selection 
of viral variants by direct-acting antivirals confers resistance and thus combination 
therapy is required to prevent viral resistance (Pawlotsky 2011).  
Even though current therapies are highly effective at clearing HCV infection, there are 
many barriers to effective clearance. First, acute infection presents with mild or no 
symptoms and thus is typically unrecognized, so knowledge of infection and need to seek 
care is minimal and the infection remains undiagnosed (Westbrook 2014). Second, the 
population most at risk for HCV infection are people who inject drugs (PWID), for whom 
obstacles to receiving effective HCV care include poverty, homelessness, addiction, 







HIV (Williams 2011, Edlin 2005). The complexity of treatment for HIV and HCV 
coinfection often requires a specialist. An economic barrier is the cost of treatment 
ranging from $8,000 for only pegylated-interferon and ribavirin therapy to $41,700 for 
triple therapy, although newly approved simeprevir and sofosbuvir are $66,000 and 
$84,000 (Chan 2013, Fair Pricing Coalition 2013). 
Finally, an immunologically interesting and unsettling point of discussion is that recovery 
does not confer protection from reinfection (Callendret 2014). In other words, continued 
exposure to HCV will negate the benefits of treatment. Therefore, methods beyond 
treatment to prevent progression to chronic infection that induces the morbidity and 
mortality caused by HCV are necessary. One approach to examining disease progression 
prevention is by studying the immune response of those able to spontaneously clear 
infection. Approximately 25% of those infected with HCV are able to clear the virus 
(Osburn 2010). Furthermore, rapid clearance of HCV reinfection indicates that a 
successful memory immune response was generated upon challenge, which is ideal for 
examining correlates of protection in a vaccine candidate. Studying the difference 
between an effective immune response able to clear the initial infection and subsequent 
reinfections to those unsuccessful at clearing infection will aid in determining correlates 











Virus characteristics  
First discovered in 1989 and formerly known as non-A, non-B hepatitis agent, hepatitis C 
virus is an enveloped, positive-stranded RNA virus from the genus hepacivirus and in the  
family flaviviridae containing approximately 9.6 kilobases (Choo 1989). After entry into 
hepatocytes, the virus uncoats and the genome is translated into a single polypeptide of 
roughly 3000 amino acids and is cleaved into three structural proteins at the amino-
terminal region: core, E1, and E2; and seven nonstructural proteins at the 
carboxyterminal region: p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B (Lindenbach 
2013a, Bartenschlager 2004). The surface glycoproteins E1 and E2 mediate binding and 
entry into hepatocytes while the nonstructural proteins manage HCV replication via RNA 
synthesis, dampening host defense mechanisms, and assembling the virus (Lindenbach 
2013a, Mazumdar 2011, Lindenbach 2013b).  
HCV genome variability 
A major challenge in the study of HCV is the variability of the virus genome. Genetic 
variability of HCV occurs both between and within genotypes. Because the virally 
encoded RNA polymerase lacks proofreading function, HCV has a high rate of evolution 
and thus diversity. HCV strains are classified based on phylogenetic analysis of sequence 
similarity into seven genotypes with more closely related groups within each genotype 
further classified into subtypes (Simmonds 1994). Sequences between genotypes differ at 
30-35% of nucleotides while sequences within genotypes differ at 10-20% of their 







world's countries, or 90% of the world's population, the most prevalent genotype was 
genotype 1 accounting for 46.2% of cases, followed by genotype 3 accounting for 30.1% 
of cases globally (Messina 2015).  
Additional HCV variability occurs within an infected individual, termed quasispecies. 
Using detailed virus phylogenetic characterization tools such as next-generation 
sequencing or pyrosequencing as opposed to Sanger sequencing, multiple variants of 
HCV can be seen in early HCV infection although a dominant variant is present in most 
samples (Abdelrahman 2015, Beerenwinkel 2011). Furthermore, during acute HCV 
infection, variants within an individual range from 1 to 7.8% based on phylogenetic 
analysis (Herring 2005). The diversity of viruses within an individual poses major 
challenges to vaccine development and drug therapies.  
Immune Response 
Innate immune response to HCV 
Although most viral pathogens induce a successful immune response able to clear 
infection, HCV has developed mechanisms to evade the immune response and persist. 
Central to host defense against viral pathogens is recognition of the invading pathogen as 
nonself by the innate immune system. Pathogen-associated molecular patterns, or 
PAMPs, are microbial components such as glycoproteins, lipopolysaccharides, 
proteoglycans, and nucleic acid motifs that are conserved through various 
microorganisms capable of recognition by the innate immune system by pattern 







proteins that activate antiviral programs. HCV is detected by innate sensing mechanisms 
such as retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) genes such as RIG-I 
and melanoma differentiation-associated protein 5 (MDA-5) that bind to the polyuridine-
rich motif of the 3’ non-translated region and its replication intermediate in the HCV 
genome, endosomal sensor toll-like receptor 3 (TLR3) detecting double-stranded RNA 
(dsRNA), toll-like receptor 7 (TLR7) that senses single-stranded RNA oligonucleotides, 
and protein kinase R (PKR) that binds to dsRNA (Saito 2008, Horner 2013, Jensen 2012, 
Chattergoon 2014). Recognition of HCV through most sensors activates kinases that 
phosphorylate signaling molecules to induce downstream transcription of antiviral and 
immunomodulatory genes, type I and type III interferons, and other proinflammatory 
cytokines that influence protein synthesis, growth regulation, and apoptosis (Horner 
2013, Jensen 2012). The interferons induced by innate sensing mechanisms inhibit viral 
replication in infected cells and signal to uninfected neighboring cells to enter an antiviral 
state (Li 2013). An important role of innate immune sensing is coordinating the adaptive 
immune response. Through antigen presentation, co-stimulatory molecules, and 
cytokines, the innate immune system promotes the initiation of the highly-specific 
adaptive immune response.  
Adaptive immune response: humoral immunity 
Although the mechanism for delay in antibody production in not known, anti-HCV 
antibodies are not detected until 7-10 weeks after exposure to HCV, while antiviral 
immune responses are often generated 5-7 days after exposure to other viruses (Netski 







Evidence of neutralizing antibody activity has been demonstrated by clearing established 
HCV infection in liver chimeric mice and protecting genetically humanized mice from 
HCV infection (de Jong 2014, Law 2008). In humans, there is evidence of association 
between rapid induction of neutralizing antibodies during the acute phase of infection and 
viral clearance (Pestka 2007). However, infected humans developing antibodies that 
neutralize distantly related HCV genotypes fail to control HCV replication with evidence 
of selection for escape variants (von Hahn 2007). Moreover, viral clearance can occur 
independent of antibody contribution, and cross-neutralizing antibody was not protective 
against heterologous virus challenge (Cooper 1999, Post 2004, Barth 2011). Further 
studies suggest an association between clearance of reinfection and generation of cross-
reactive neutralizing antibodies, but this was not true for all subjects (Osburn 2010). 
Although the role of neutralizing antibodies remains unclear, this evidence indicates that 
other methods of adaptive immunity contribute more to HCV viral clearance.    
Adaptive immune response: cellular immunity 
Cellular immune responses are thought to play a vital role in clearance of HCV. More 
significantly, virus-specific CD8 T cells are the primary adaptive immune effector cells 
facilitating HCV clearance. Briefly, CD8 T cells recognize 8-10 amino acid long peptides 
bound to major histocompatibility complex (MHC) class I molecules on antigen 
presenting cells or infected target cells. Virus-specific CD8 T cells have effector function 
through cytolytic properties, such as production of perforin and granzymes, Fas-FasL 
interaction, or production of antiviral cytokines such as IFN-γ upon recognition of 







CD8 T cells begin to appear 6-8 weeks after infection (Cox 2005, Thimme 2002). This 
delay in cellular response is due to delaying of priming of CD8 T cells rather than 
recruitment of HCV-specific T cells (Shin 2011). Delays of cellular immune responses 
compared to other viral infections are seen in both chronic and cleared HCV infections 
(Cox 2005).  
Spontaneous resolution of infection is associated with robust HCV-specific CD8 T cell 
responses. Successful responses are associated with increased breadth and magnitude of 
epitopes recognized, and enhanced ability to produce cytokines upon epitope recognition 
(Lauer 2004, Abdel-Hakeem 2014, Osburn 2010, Ciuffreda 2008). The ability of CD8 T 
cells to produce several effector cytokines and molecules is associated with HCV 
clearance (Badr 2008).  
During early infection, CD4 T cells target epitopes broadly regardless of outcome (zur 
Wiesch 2012). However, there is an inverse correlation between the number of detected 
responses of CD4 T cells and time to onset of symptoms in infections that become 
chronic (zur Wiesch 2012). No such correlation is apparent for spontaneously resolved 
infections (zur Wiesch 2012). Spontaneous resolution is correlated with vigorous CD4 T 
cell proliferative responses (zur Wiesch 2012). Importantly, the loss of broad CD4 T cell 
response is not causative of progression to chronic HCV but rather a result of other 
mechanisms that induce a contraction of responses (zur Wiesch 2012). In CD4 T cell 
depletion studies, HCV RNA levels were lower in reinfection after CD4 T cell depletion 







that CD4 T cells are not the primary antiviral effector cells in HCV clearance (Grakoui 
2003).     
Viral escape of immune system 
Although an immune response occurs upon HCV infection, it is ineffective and leads to 
chronic infection in approximately 75% of adults exposed (Thomas 105, CDC 2014). 
Pressure from both cellular and humoral immunity during chronic infection leads to 
selection of escape variants and continued viremia (von Hahn 2007). The high replication 
rate and lack of proofreading activity in the RNA-dependent-RNA polymerase leads to 
multiple variants that can escape the adaptive immune response.   
Genetic associations with infection outcome    
Genetic factors have been implicated in the protective function in many diseases. For 
example, subjects with CCR5 receptor deletion display resistance to HIV infection 
(Steinberger 2000). In HCV, some genetic associations with infection outcome have been 
defined as well. Spontaneous resolution of infection was associated with a single 
nucleotide polymorphism (rs12979860) 3 kilobases upstream of the gene encoding the 
type III interferon (IFN)-λ3, also known as IL28B, and the C/C genotype (Thomas 2009). 
Several class I and class II HLA alleles are associated with HCV viral clearance. HLA 
class I alleles with the most reproducibly positive association with spontaneous clearance 
are HLA-B*27, HLA-B*57, and HLA-Cw*01 (Schmidt 2011). Additional studies have 
noted positive associations with viral clearance and MHC class I alleles HLA-A*11:01, 







DQB1*03:01 (Mina 2015, Thio 2001). The association of HLA molecules with outcome 
further supports the importance of the adaptive immune response to reinfection clearance.   
Current knowledge of chronic versus acute versus reinfected clearers  
Importance of reinfections 
Understanding the immune correlates of protection is the first step to developing an 
effective vaccine. Both chimpanzee and human studies noted that HCV reinfection 
resolved by the immune response is associated with more rapid viral clearance, decreased 
HCV RNA serum titer, and decreased liver disease compared to primary infection 
(Nascimbeni 2003, Osburn 2010). These observations are indicative of an adaptive 
immune component involved in immunity to HCV reinfection. Although clearance of the 
initial infection and never becoming reinfected is indicative of a protective immune 
response, the ability to clear reinfection guarantees not only continued exposure, but a 
successful response upon rechallenge. The goal of prevention of progression to chronic 













EXAMINING BREADTH AND SPECIFICITY OF T CELL EPITOPES DURING 
REINFECTION 
Introduction 
Current studies of HCV reinfection 
The most efficient and effective way to study the immune response during reinfections is 
by prospective studies of populations at high-risk for acquiring HCV. Because only 20-
30% of initial infections are cleared, these studies need to be large to ensure that 
reinfections are observed (Osburn 2010). Therefore, few studies have characterized the 
human immune response during HCV reinfection. The Montreal Acute Hepatitis C 
Injection Drug User Cohort Study characterized the cellular immune response during 
HCV reinfection by examining the magnitude and breadth of the T cell response, 
proliferative capacity upon HCV-peptide stimulation, cytokines produced by HCV-
specific T cells, and phenotyping HCV-specific T cells (Abdel-Hakeem 2014). 
Additionally, a prospective study of intravenous drug users in Baltimore characterized 
reinfection by examining infection kinetics, breadth and magnitude of T cell response, 
and appearance of neutralizing antibodies (Osburn 2010). Significant findings indicated 
that spontaneous resolution of reinfections is associated with an increase in breadth and 
magnitude of the HCV-specific T cells (Abdel-Hakeem 2014, Osburn 2010). The 
proliferative capacity of HCV-specific CD4 and CD8 T cells in subjects who clear 
reinfection is greater than in those who become chronically infected upon reinfection 
(Abdel-Hakeem 2014). Similar to those who resolve acute infection, spontaneous 







specific T cells compared to reinfections that become chronic (Abdel-Hakeem 2014). 
Interestingly, clearance of reinfection was more suggestive of an association between the 
level of individual cytokine production rather than the polyfunctionality of the HCV-
specific CD4 T cells, but in CD8 T cells clearance was associated with both the level of 
cytokine production and polyfunctionality (Abdel-Hakeem 2014).  
Although the Montreal prospective cohort provides valuable insight into reinfection T 
cell dynamics, the subject history is incomplete. Information on genotypes for many of 
the initial infecting HCV subtype were not provided because subjects entered the study 
with anti-HCV antibodies already present, indicating a previous infection. Obtaining viral 
sequence information during acute infection reduces the possibility that a reinfection is 
not merely a spike in HCV RNA during the initial infection since variable levels of 
viremia, including brief periods below the level of detection of standard assays has been 
documented (Abdelrahman 2015, Cox 2005b). In addition, without identification of the 
infection in the initial acute phase of infection, it is not possible to know how many 
preceding infections the patient has experienced. Therefore, it is integral to ensure a strict 












Methods    
Baltimore Before and After Acute Study of Hepatitis (BBAASH) cohort 
As a prospective study of HCV, subjects at high risk for infection were recruited to enter 
the Baltimore Before and After Acute Study of Hepatitis (BBAASH) in Baltimore, 
Maryland. Participants were 18-65 year old active injection drug users with no detectable 
anti-HCV antibodies or HCV virus in peripheral blood. Drug and injection practice 
counseling in addition to referral to medical treatment, needle exchange, and other 
services were provided for study subjects. Written informed consent was obtained from 
each study subject, and the study protocol was approved by the Institutional Review 
Board of the Johns Hopkins School of Medicine. Blood was donated by study subjects at 
one month intervals for anti-HCV antibody and HCV RNA viral load testing on either 
serum or plasma. Upon HCV RNA detection, units of blood were drawn every three 
months to obtain larger amounts of peripheral blood mononuclear cells (PBMCs) for 
cellular analysis. A reinfection was defined as phylogenetic difference of the Core-E1 
region by 5%, and at least 60 days of aviremia determined by either viral load COBAS 
Taqman reverse transcription PCR quantitative assay and/or qualitative Core-E1 
genotype assay between infections.  The subject characteristics are summarized in Tables 
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Notes: All study subjects are Caucasian. 1. IL28b SNP: rs12979860; 2. Reinfection 
defined as a new infection following at least 60 days of aviremia determined by 
quantitative viral load RT-PCR and qualitative Core-E1 detection with greater than 5% 
phylogenetic difference in HCV Core-E1 nucleotides; 3. N/A signifies genetic 
information not available. Arrows () indicate new infection while dashes (/) indicate a 



















Table 2. Summary of reinfected subjects 
Genetic factor  Male (n=5) Female (n=3) Total 









60% 67% 63% 
Persistent 
HLA 
A*23:02, C2C2 0% 0% 0% 
 Note: Genetic information unavailable for one subject  
 
Table 3. Individual chronic study subject characteristics for FACS analysis 
Patient 
code 
Sex HLA class 
I allele 









































Limitations to study design  
Although the prospective BBAASH monthly study enables in-depth opportunities to 
examine HCV infection dynamics, inherent limitations restrict complete comprehensive 
analysis of the immune system. These limitations can be grouped into the technical 
aspects, subject characteristics, and virus kinetics.  
The first, technical limitations, refers to the assays used to qualitatively and quantitatively 
assess the virus, and the method to determine recognized HCV epitopes. The limit of 
detection for genotyping is 100 International Units (IU)/mL, while the limit of detection 
for quantitative determination of viral load is 50 IU/mL. This means that virus could be 
circulating but is below limit of detection of the assay. Additionally, the ELISpot assay 
that qualitatively and quantitatively defines recognized T cell epitopes uses genotype 1a 
virus peptides as antigens, and recognition of epitopes restricted to other genotypes may 
be less well detected in this assay. Although there are other genotypes of HCV in 
circulation, 1a is the most common genotype, representing roughly 75% of total 
genotypes prevalent in the US (Messina 2015).  
The second constraint that limits the analysis of the immune system is subject 
characteristics. In order to perform cellular analysis, large blood donations, called units, 
are required to have enough PBMCs. Units can be drawn no more frequently than every 8 
weeks. If subjects are ineligible for a large blood draw, for example having poor veins or 








The characteristics of HCV infection in conjunction with the cohort study format limit 
reinfection analysis. HCV reinfection is associated with attenuated virus kinetics such as 
shorter duration of viremia and decreased magnitude of circulating virus (Osburn 2010). 
Subjects in the BBAASH cohort donate blood monthly, but the decreased duration of 
viremia upon reinfection permits a reinfection to be cleared between the monthly draws 
and thus not be detected. Another characteristic of HCV infection that limits 
comprehensive analysis is a control comparison. Chronically infected individuals tend to 
lose T cell responses over time, and thus time-matching the course of infection of a 
chronic infection to a reinfection time point starting from the initial infection is not ideal. 
Therefore, in the following analyses, each reinfection is treated as a ‘new infection’ and 
compared to both the acute infection of the same subject and the acute infection of a 
chronically infected subject. However, HCV-specific T cell responses in acute infection 
are not apparent until 6-8 weeks after infection (Cox 2005a, Thimme 2002). In our study, 
we compare the T cell response in reinfection to the earliest time point that HCV-specific 
responses were detected in the primary infection. The strict definition of reinfection as 60 
days of aviremia followed by infection with a new HCV virus with at least 5% difference 
in Core-E1 sequence ensures analysis of reinfection rather than recurrence of viremia 
from the initial infection.   
Determination of HCV viral levels  
 A quantitative value of HCV viral level was determined from either serum or plasma 







polymerase chain reaction (RT-PCR) assay with the Abbott RealTime HCV RNA assay. 
The sensitivity for this assay is 50 IU/mL.  
HCV genotyping 
HCV genotype was determined by performing phylogenetic analysis of HCV Core-E1 
sequence obtained from either patient serum or plasma stored at -80° Celsius. Viral RNA 
was extracted using QIAGEN's QIAamp® MinElute® Virus Spin Kit according to the 
manufacturer's instructions. The positive control was plasma from subjects with known 
sequence and viral load while the negative control was Millipore water in place of 
plasma. RNA was extracted from 600 µl (cleared subjects) and 200 µl (acutely infected) 
of plasma or serum. An RT-PCR reaction was performed first, and the products were 
converted to cDNA in a second round. Samples were run on a 1% agarose/tris-borate 
EDTA gel with ethidium bromide for approximately 30 minutes at 100-130 volts. Bands 
were detected using a transilluminator. If positive, the PCR product was purified using a 
Qiagen kit following manufacturer's instructions. DNA was sequenced at the Core 
Sequencing facility at Johns Hopkins.  Sequences were trimmed to equal length and 
aligned with BioEdit using ClustalX.  
Enzyme-Linked ImmunoSpot (ELISpot) assay 
Using a multichannel pipet, an ELISpot plate was coated with recombinant mouse anti-
human IFN-γ antibody (MAbTech clone#1-D1K). The ELISpot plate was incubated at 4° 
Celsius overnight. Cells were taken immediately from -160° Celsius liquid nitrogen 







added to cells, washed twice, and resuspended to final resting concentration of 3 million 
cells per milliliter in tissue culture flask overnight in CO2 incubator at 37° Celsius. After 
overnight incubation, mouse anti-human IFN-γ antibody was discarded from ELISpot 
plates and each plate was washed four times with sterile 1X PBS. To block the plate, 10% 
FBS in RPMI (R10) was added to each well and incubated for two hours at 37° Celsius. 
PBMCs that had rested overnight were resuspended to a final concentration of 4 million 
cells per milliliter in R10. After blocking the ELISpot plate for two hours, R10 was 
discarded. HCV peptide diluted to 20 µg/ml in R10 was added to each well. Using a 
multichannel pipet, 200,000 cells were added to each well. In other words, 200,000 
PBMCs at 2 million cells per milliliter were being stimulated by 10 µg/ml of peptide in a 
total volume of 100 µl of R10. PBMCs with peptide were incubated for 15-20 hours at 
37° Celsius. After incubation, the plate contents were discarded and blotted dry. The plate 
was washed 7 times with wash buffer (0.05% Tween20 in 1X PBS). Using a 
multichannel pipet, biotinylated mouse anti-human IFN-γ monoclonal antibody 
(MAbTech clone 7-B6-1) detection antibody was added to each well and incubated for 3 
hours at room temperature. After incubation, the plate contents were discarded and the 
plate was washed 4 times. Alkaline phosphatase-conjugated anti-biotin monoclonal 
antibody (aBio-ALKPHOS, Vector Laboratories) was added to each well of the plate and 
incubated for 2 hours at room temperature. After incubation, the contents of the plate 
were discarded and washed 4 times with wash buffer. Plates were developed with filtered 
BCIP/NBT solution for 10 minutes at room temperature. After developing, contents of 







development. The plate gasket was removed to allow the plate to dry overnight. Spot-
forming cells were quantified at the JHU Immunology core.  
 
Results 
Greater magnitude, but not breadth, is associated with HCV reinfection. 
The breadth and specificity of T cell responses was examined using ELISpot. Previous 
studies have indicated that clearance of reinfection is associated with increase in breadth 
of HCV-specific T cell response and higher magnitude of interferon gamma production 
(Abdel-Hakeem 2014).  At each visit where large numbers of PBMCs were available, 
cells were tested on the same plate in an interferon gamma ELISpot assay with individual 
peptides that previous ELISpot screens indicated were recognized by that subject's T 
cells. The peptides tested included both optimal epitopes (peptides that were previously 
determined to be of optimal length for recognition) and longer peptides from overlapping 
peptide pools that span the whole HCV polyprotein. The magnitude of the response is 
indicated by the total number of SFCs while the breadth of the response is defined as the 
number of different epitopes recognized. For each reinfection, the magnitude and breadth 
of the anti-HCV cellular immune response was obtained using ELISpot (Figure 1A-H). A 
summary of the viral RNA levels and HCV T cell epitopes recognized and magnitude of 
the response is presented in Figures 2A-B. If multiple units were tested during a 







The total magnitude of the anti-HCV interferon gamma response for the first reinfection 
is greater than the magnitude of response during the primary infection for every subject 
tested. This increase is seen in both reinfections that become chronic and reinfections that 
are cleared. There is a significantly greater interferon gamma response to HCV peptides 
in the first reinfection than the primary infection (Figure 3A). However, subsequent 
reinfections are not uniformly associated with continued increases in the magnitude of the 
T cell response. While the magnitude of the T cell response remains greater than in 
primary infection, some second and third reinfections are associated with declining 
magnitude of the T cell response compared to the magnitude at the first reinfection.  
In contrast, the breadth of the T cell response is not significantly greater with reinfection 
than in primary infection. While new T cell epitopes are almost uniformly targeted with 
each new infection, there is also loss of T cell epitope recognition such that the number of 
total epitopes recognized during each reinfection is not always greater than the number of 
epitopes recognized during the initial infection. There is no statistically significant 
difference between the number of total epitopes recognized during the first reinfection 
than during the primary infection (Figure 3B).  These results suggest that an increase in 
magnitude, but not an increase in breadth, is associated with reinfection.  
We compared the total number of epitopes recognized during the last available 
reinfection time point to the number of epitopes recognized during the initial infection. 
There was a statistically significant increase in the number of new epitopes recognized 
upon the last reinfection to the initial infection for all subjects (p=0.019 paired t-test; 







difference in the number of new epitopes recognized upon first reinfection compared to 
initial infection (p=0.156 Wilcoxon Signed Rank Test; p=0.125 Paired t-test). 
Cleared reinfections and persistent reinfections have no statistically significant 
difference in the breadth or magnitude of anti-HCV T cell interferon gamma 
secretion. 
In contrast to primary infection, most reinfections are cleared. However, roughly 17% 
persist with resultant chronic infection (Osburn 2010). In this analysis, three subjects 
were unable to clear a reinfection. Although two subjects became persistently infected 
during their first reinfections, the third developed persistent infection following the 
second reinfection. In order to control for a persistent reinfection occurring on the second 
reinfection, one subject was randomly chosen using a random number generator from the 
three subjects who cleared second reinfections and the second reinfection from that 
subject was chosen for analysis. The first reinfection was used as a comparator for the 
two subjects with persistence upon the first reinfection.  
A comparison of the breadth and magnitude of the fold change of cleared versus 
persistent reinfections revealed no statistically significant differences. The magnitude of 
interferon gamma produced during reinfection compared to the initial infection is 
presented as the fold change in Figure 4A. However, there was no difference in the 
magnitude of anti-HCV response between those unable to clear the reinfection and those 







reinfection. However, the small number of subjects limits the power to detect statistical 
significance in this study.  
Similar findings were seen with breadth of response. The ratio of the number of total 
epitopes recognized during the reinfection to the number of epitopes recognized in the 
first infection was compared between cleared reinfections and persistent reinfections. 
There was no difference between cleared reinfections and persistent reinfections in the 
total number of epitopes recognized in reinfection versus initial infection (Figure 4B). 
Further analysis investigated whether there was a difference in the number of new 
responses that developed upon reinfection between cleared reinfections and persistent 
reinfections. There was no statistically significant difference between cleared reinfections 
and persistent reinfections in the development of new responses upon reinfection 
compared to initial infection (Figure 4C). These results indicate that the breadth of anti-
HCV epitopes recognized upon reinfection does not correlate with outcome of 
reinfection.   
Although an increase in breadth of response from initial infection to first reinfection for 
all subjects, (including those who clear and those who develop persistence upon 
reinfection) was not significant, we wanted to examine if there were statistically 
significant differences in subjects who clear all reinfections. No statistically significant 
association was found in the total number of epitopes recognized from initial infection to 
first reinfection in subjects who clear all reinfections (p=0.250 Wilcoxon Signed Rank 
Test, Paired t-test failed normality). A similar analysis was performed looking at the 







subjects who become chronically reinfected. Similarly, there was no statistically 
significant change in the total number of epitopes recognized comparing initial infection 
to persistent reinfection in subjects who do not clear reinfection (p=0.478 Paired t-test).  
An indication of a robust immune response is the ability to develop new responses. T 
cells may respond to epitopes during reinfection that were not recognized during the 
initial infection, suggesting an ongoing response to new HCV exposures. We analyzed 
this development in various ways. First, as all subjects are reinfected at least once, we 
compared the number of new epitopes recognized during first reinfection in those who 
clear infection to those who develop persistent reinfection, but this was not significantly 
different between the two groups (p=0.250 Mann-Whitney Rank Sum Test; t-test failed 
normality). As previously described, the subject who became persistently infected upon 
second reinfection was randomly matched to a second reinfection of a subject who 
cleared. However, some subjects become reinfected multiple times and recognize new 
epitopes during every reinfection. To take into account multiple reinfections, we took the 
average of all the new epitopes gained during every reinfection and compared this 
average between subjects who clear all reinfections and subjects with persistence upon 
reinfection. However, there was no statistically significant difference in the average 
number of new epitopes in all reinfections between subjects who do and do not clear 
reinfection (p=0.250 Mann-Whitney Rank Sum Test because t-test failed normality).  
A hallmark of chronic HCV infection is the loss of interferon gamma secretion in 
response to HCV peptides over time. To examine if subjects who are unable to clear 







the first reinfection that were recognized during the initial infection between subjects who 
clear the reinfection and subjects who do not clear the reinfection. For the subject who 
became chronic upon second reinfection, the epitopes recognized during the second 
reinfection was compared to the initial infection. This was randomly matched to another 
subject and the same analysis performed. However, there was no statistically significant 
difference in the number of epitopes lost in repeated clearers and in reinfections that 
become chronic (p=0.482, t-test).  
 
No immunodominance in epitopes recognized by reinfected subjects. 
To examine whether reinfection is associated with recognition of a particular epitope or 
region of the HCV polypeptide, all of the HCV epitopes recognized by each reinfected 
subject were mapped to the HCV polyprotein. Epitopes are recognized throughout with 
no apparent immunodominance (Figure 5). Further analysis was performed to determine 
if persistent reinfection is associated with responses to a common epitope. There was no 
apparent immunodominance in reinfections that become persistent. The red dots in Figure 
5 indicate epitopes recognized by subjects at the reinfection that becomes persistent. 
These results suggest no difference in the region of the HCV polyprotein targeted by T 























Figure 1A. Reinfected Clear Subject 57 
 
Figure 1A-H. Plot of viral load and epitope response. Each slice of the pie chart 
denotes a peptide epitope, and the size of the slice represents the proportion of total 
response. The size of the pie denotes the magnitude. A-H represent different 
subjects tested. Black dots on the viremia area denote time points when HCV viral 












































































Figure 2A. Magnitude of ELISpot response for all subjects. Dashed lines indicate 








Figure 2B. Breadth of ELISpot response for all subjects. Dashed lines indicate 








Figure 3A. Magnitude of ELISpot response for reinfected subjects from primary 








Figure 3B. Breadth of ELISpot response for reinfected subjects from primary 








Figure 4A. Ratio of the total SFC comparing first reinfection to primary infection. 
Each dot denotes one subject comparing the total magnitude of ELISpot response of 








Figure 4B. Ratio of number of epitopes recognized from first reinfection to primary 








Figure 4C. Ratio of new epitopes recognized upon reinfection. Each dot denotes the 
ratio of epitopes recognized in first reinfection that were not recognized during the 
primary infection to the total number of epitopes recognized during the first 
infection.  










Figure 5. Mapping of recognized epitopes along HCV polyprotein. Each dot denotes 
a location along the HCV genome that was recognized. Red dots indicate epitopes 















IMMUNOPHENOTYPING OF HCV-SPECIFIC CELLS DURING 
REINFECTION 
Introduction: Surface molecule definitions 
Flow cytometry as a tool to examine phenotype 
Characterizing HCV-specific cells based on activation, memory, and exhaustion status as 
well as T-cell subsets was performed with flow cytometry, "arguably the most powerful 
technology available for probing human immune phenotypes" (Maecker 2012). This 
technology allows for single cell analysis of multiple surface molecules, intracellular 
cytokines, and protein expression. Comprehensive phenotype of HCV-specific cells 
during reinfection was obtained using a twelve-color polychromatic panel examining cell 
surface protein expression. Figure 5 demonstrates the flow cytometry experiment 
performed.  
 







Markers of T-cell subsets 
CD45RA is a transmembrane protein tyrosine phosphatase and the expression of various 
splice variants of this molecule indicates whether T cells have encountered antigen. T 
cells that have not yet encountered antigen express CD45RA, while T cells express the 
splice variant CD45RO upon activation. Terminally differentiated effector memory cells 
revert back to CD545RA expression (Wills 1999). Expression of CC-chemokine receptor 
7 (CCR7) controls homing of T cells to secondary lymphoid organs such as the lymph 
nodes (Forster 1999). As CD45RA is re-expressed after a period of time since antigenic 
stimulation, the CD45RA+ subset includes both naïve and non-naïve T cells, thus the 
combination of CD45RA and CCR7 is useful to define T cell differentiation (Carrasco 
2006). Moreover, the combination of CD45RA and CCR7 expression defines classical T 
cell subsets as: naïve T cells are CCR7+CD45RA+, central memory T cells are 
CCR7+CD45RA-, effector memory T cells are CCR7-CD45RA-, and terminally 
differentiated effector memory T cells or Temras are CCR7-CD45RA+ (Maecker 2012, 
Sallusto 2004, Appay 2008). These T cell subsets differ in their effector function 
potential and ability to home to secondary lymphoid organs. Circulating CD8+ T cells 
from healthy individuals range from 57-64% naïve, 7-15% central memory, 10-21% 
effector memory, and 9-26% Temras (Thome 2014, Geginat 2003). Central memory 
cells, defined as CCR7+CD45RA-, possess the ability to migrate to secondary lymphoid 
tissues and respond to antigenic stimulation with rapid proliferation and differentiation 
into effector cells (Sallusto 2004). Conversely, effector memory cells, CCR7-CD45RA-, 
respond to antigenic stimulation with rapid effector function including release of perforin 







potential compared to central memory cells (Sallusto 2004). Temras, defined as CCR7-
CD45RA+, are the most differentiated T cells with the greatest cytolytic capacity and 
carry the largest amount of perforin and granzyme B and express high levels of Fas 
ligand (Sallusto 2004, Hamann 1997). HCV-infected individuals have lower percentages 
of naïve CD8+ T cells and higher percentages of Temra cells compared to CD8+ T cells 
from healthy individuals (Shen 2010).  
Molecules of activation  
The ectoenzyme CD38, a defining molecule of activation, catabolizes nicotinamide 
adenine dinucleotide (NAD+), leading to increased intracellular calcium-mobilizing 
compounds (Malavasi 2008). Accumulation of extracellular NAD induces ADP 
ribosylation via ecto-mono-ADP-ribosyltransferases to initiate apoptosis due to decreased 
calcium influx of activated T cells (Han 2000, Krebs 2005, Seman 2003). Therefore, 
CD38 allows selective expansion of primed T cells. Upon CD38 ligation with its 
receptor, signal transduction occurs that produces cytokines such as IL-6, granulocyte-
macrophage colony-stimulating factor (GM-CSF), IFN-γ, and IL-10 (Malavasi 2008). 
Importantly, CD38 on T cells has interesting implications in chronic viral infections. For 
example, CD8+/HLA-DR+/CD38- cells are associated with undetectable HIV plasma 
viral load in the absence of therapy (Saez-Cirion 2007).  
During chronic HCV infection, activation molecules CD38 and HLA-DR are upregulated 
on CD8+ T cells compared to CD8+ T cells from healthy controls, and the expression 
level of HLA-DR, but not CD38, negatively correlates with circulating HCV viral load 







of a molecule on individual cells, of CD38 at the first study time point during infection 
was higher on HCV-specific T cells in chimpanzees that subsequently resolved infection 
than on HCV-specific T cells in those chronically infected (Shin 2013).  
Molecules of exhaustion 
Chronic antigenic stimulation, as occurs in cancer and in chronic viral infections, results 
in T cell exhaustion. This dysfunctional T cell state develops in a stepwise manner with 
gradual loss of cytokines and effector molecules starting with IL-2 and with IFN-γ among 
the last lost (Wherry 2011). Additionally, T cell dysfunction is characterized by 
overexpression of inhibitory receptors, downregulation of TCR signaling molecules, 
decreased expression of metabolic and translational machinery molecules, and altered 
chemotaxis, migration, and adhesion gene expression (Wherry 2007). Phenotypically 
exhausted T cells are seen in many persistent infections, such as lymphocytic 
choriomeningitis virus (LCMV) in mice, and hepatitis B virus (HBV), HCV, and human 
immunodeficiency virus (HIV) in humans (Zajac 1998, Boni 2007, Bengsch 2010, Day 
2006). Transcription signatures in T cell exhaustion differ from a state of anergy, which 
occurs when T cells recognize antigen via the TCR but lack costimulation (Wherry 
2007).  
Programmed cell death protein-1, also known as PD-1 and CD279, contains an 
immunoreceptor tyrosine-based inhibition motif (ITIM) it its cytoplasmic tail, which, 
upon surface binding to its ligand PD-L1 or PD-L2, inhibits T cell activation and T cell 
receptor-CD28 signaling (Freeman 2000, Ishida 1992, Latchman 2001). The outcome of 







some studies. Specifically, in the first six months of infection, subjects who cleared 
infection had lower PD-1 levels on HCV-specific cells than those who failed to clear 
infection, although these differences were less pronounced beyond six months after initial 
infection (Rutebemerwa 2008, Urbani 2006). However, additional studies demonstrated 
high PD-1 expression on HCV-specific CD8 and CD4 T cells during acute infection 
regardless of clinical outcome, but noted that the percent of PD-1+ cells declined after the 
acute phase of infection in spontaneous resolution, but not in those developing chronic 
infection (Kasprowicz 2008, Urbani 2006). This is in agreement with the proposal that 
PD-1 is an activation marker rather than an exhaustion marker during acute HCV 
infection because upregulation during acute infection did not inhibit clearance (Shin 
2013). Additionally, lower levels of PD-1 were seen in spontaneous resolution of cleared 
reinfection (Abdel-Hakeem 2014).  
While the function of T-cell immunoglobulin and mucin domain-containing molecule 3 
(Tim-3) has yet to be fully elucidated, there is a correlation between T cell dysfunction in 
chronic infection and Tim-3 expression (Fujita 2014, Jones 2008, Golden-Mason 2009). 
In HIV, Tim-3 is upregulated on both CD4+ and CD8+ T cells from chronic infection 
compared to uninfected individuals, and although Tim-3+CD8+ T cells had higher levels 
of perforin, they were defective in their ability to degranulate and have decreased ability 
to secrete effector cytokines IFN-γ and IL-2 (Jones 2008, Sakhardi 2012, Zhang 2015). In 
chronic HCV infection, Tim-3 is overexpressed on total CD4+ and CD8+ T cells and 
with highest frequency on HCV-specific T cells containing decreased ability to secrete 
effector cytokines tumor necrosis factor (TNF)-α and IFN-γ (Golden-Mason 2009). 







HCV-specific T cell dysfunction by augmenting proliferation and increasing cytokine 
production of IFN-γ and TNF-α (Golden-Mason 2009, McMahan 2010). Similarly, 
blockade of PD-1 and its ligand enhances proliferation of HCV-specific CD8 cells 
(Urbani 2006).  
Coexpression of Tim-3 and PD-1 correlates with increased T cell dysfunction, with 
higher levels of other inhibitory receptors such as LAG3 and 2B4, with decreased 
proliferative capacity upon peptide stimulation, and with reduced ability to secrete 
effector cytokines IFN-γ, TNF-α, and IL-2 (Jin 2010). Dual expression of Tim-3 and PD-
1 on HCV-specific CD8 T cells during acute infection is associated with viral persistence 
as infections spontaneously resolved were characterized by a lower frequency of dual 
positive HCV-specific CD8 T cells than dual negative compared to chronic infection 
(McMahan 2010).  
 







Molecules of activation/homeostasis  
The combination of coreceptor CD28 and homeostatic cytokine interleukin-7 (IL-7) 
receptor-α CD127 can discriminate dynamics of T cell function. More specifically, 
CD28+CD127+ indicates resting or unstimulated T cells, CD28+CD127- T cells are 
receiving IL-7 signals, CD28-CD127+ suggests a previous TCR-driven response, and 
CD28-CD127- is the phenotype of antigen-activated effector cells (Thome 2014). IL-7 is 
essential for regulating CD8 T cell homeostasis, and thus expression of its receptor 
CD127 is an indicator of cells more likely to survive and differentiate (Schluns 2000). 
During acute infection of subjects who develop chronic infection, the percent of CD127 
expression was decreased in CD8+ T cells compared to uninfected controls, while CD127 
levels on CD8 T cells in subjects who resolved HCV infection were not significantly 
different from controls (Golden-Mason 2006). A decrease in IL-7 receptor CD127 was 
observed on HCV-specific T cells during the reinfection that resolved but not on HCV 
specific T cells in reinfections that become chronic (Abdel-Hakeem 2014). 
 
Methods 
Immunophenotyping using polychromatic flow cytometry 
PBMCs stored at -160° Celsius liquid nitrogen were rapidly transferred into a 37° Celsius 
water bath to thaw. Using the drip method, 15 ml of R50 was added to cells. Cells were 
centrifuged at 400g for 5 minutes and the supernatant was decanted. Cells were 







hemocytometer. Cells were centrifuged at 400g for 5 minutes. After centrifugation, the 
supernatant fluid was decanted. Cells were washed with 1X PBS, centrifuged at 400g for 
5 minutes, decanted, and resuspended so that the final cell concentration was 1 million 
cells per milliliter of 1X PBS. Staining occurred in four sequential incubations: 
aquaviability, pentamer addition, surface stains, and fixation. For aquaviability staining, 
1ul of reconstituted fluorescent reactive dye was added to each milliliter of cells and 
incubated at 4° Celsius for 30 minutes. The tube of cells was filled with FACS buffer 
(0.1% BSA, 0.1% sodium azide in 1X PBS), centrifuged at 400g for 5 minutes, decanted, 
and resuspended at 1 million cells per milliliter of FACS buffer. For each test, 1-2 million 
PBMCs were allocated into individual Falcon 5ml polystyrene round-bottom FACS 
tubes. Each tube was filled with FACS buffer to wash, centrifuged at 400g for 5 minutes, 
and decanted. Prior to multimer staining, each multimer was centrifuged at 4° Celsius 
14,000g for 7-10 minutes. The fluorotag was centrifuged at 4° Celsius at 14,000g for 3 
minutes. Multimer staining was performed for 10 minutes at room temperature in the 
dark.  After washing twice for 5 minutes at 400g in FACS buffer, cells were pelleted and 
directly stained with the following antihuman antibodies: CD8-AlexaFluor700 (clone 
SK1, Biolegend), CD4-PE-CF594 (clone RPA-T4, BD Horizon), HLA-DR-BV421 
(clone G46-6, BD Biosciences), CD38-APC-H7 (clone HB7, BD Biosciences), CD28-
PerCP-Cy5.5 (clone CD28.2, BD Biosciences), CD127-FITC (clone eBioRDR5, 
eBioscience), CD45RA-PE-Cy7 (clone HI100, Biolegend), CCR7-BV711 (clone 150503, 
BD Horizon), Tim-3-PE (Clone 344823, R&D Systems), PD-1-BV605 (clone EH12.2H7, 
Biolegend) and APC fluorotag (ProImmune) for unlabeled pentamers in BV brilliant 







and ProImmune. After two further washes with FACS buffer, cells were fixed with 150ul 
of 2% formaldehyde for 1 hour at 4° Celsius. Cells were washed twice and resuspended 
in 150ul of FACS buffer. Multiparameter flow cytometry was performed using a Becton 
Dickinson LSRII equipped with red (635nm), violet (407nm), blue (488nm), and green 
(532nm) lasers using FACSDiva software. FCS data files were analyzed using FlowJo 
software version 10.0.7 for Windows 7 (Tree Star, Inc.).  Gating was based on 
fluorescence-minus-one (FMOs), with a representative FACS plot shown in Figure 8.  
 
Results 
MFI of individual molecules reveals no highly pronounced changes in expression of 
molecules upon reinfection. 
To determine differences in molecule expression on HCV-specific CD8 T cells upon 
reinfection, we examined the median fluorescence intensity (MFI) within an individual. 
Analysis of the MFI demonstrates the expression level of molecule on the population of 
cells. The MFI of pentamer+CD8+ T cells was divided by the MFI of total CD8+ T cells 
to give a ratio. Therefore, any number above one implies that the MFI on the HCV-
specific T cells is greater than the MFI on total CD8+ T cells. Conversely, any ratio 
below one indicates that the MFI on HCV-specific T cells is lower than total CD8+ T 
cells. The results from individual subjects are summarized in Figure 9. Each dot indicates 







different pentamers used. The vertical lines for each reinfected subject mark the first 
point of clearance and the first time point of new virus detected.  
For T cell phenotypic analysis, three subjects who cleared every reinfection, one subject 
who became chronic upon reinfection, and two subjects chronically infected were 
analyzed. Therefore, phenotype of HCV-specific T cells can be compared in various 
ways. First, reinfections can be compared to the initial infection within a subject. This 
method reveals changes in adaptive immune responses upon reinfection. Second, acute 
infections can be compared between chronic and reinfected subjects. This comparison 
could lead to differences in the initial immune response that lead to failure to control 
virus. Third, the first reinfection of the subject who becomes chronic can be compared to 
the first reinfections of subjects that clear all reinfections. This final method of analysis 
will reveal deficits in response that result in inability to clear reinfection.  
Molecules specifying T cell subsets, CCR7 and CD45RA, varied depending on presence 
of virus. CCR7 expression was greater on HCV-specific T cells compared to total CD8 T 
cells upon clearance of virus in most subjects that clear reinfections. Within subjects who 
clear all reinfections, the CCR7 on HCV-specific T cells tended to increase upon 
clearance of detectable virus and decreased upon reinfection. However, there was no 
apparent difference in CCR7 expression between reinfections within a subject as shown 
in Figures 9A-C. In comparison, CCR7 expression on HCV-specific T cells in chronic 
infections varied depending on the pentamer as shown in Figures 9D-E. Some HCV-







throughout all available time points, while other pentamers had a lower or the same levels 
of CCR7 on HCV-specific T cells compared to total CD8.  
Upon clearance of initial infection, CD45RA tended to increase on HCV-specific T cells 
but did not always return to levels present on total CD8+ T cells. In subjects who cleared 
reinfection, CD45RA fluctuated depending on presence of virus, although this variation 
was only maximum four times greater than total CD8+ T cells in one subject. When virus 
is present in subjects who clear reinfection, CD45RA had lower expression on HCV-
specific CD8+ T cells compared to the total CD8+ T cell population. There was no 
apparent difference in CD45RA expression upon subsequent reinfection. However, for 
chronically infected individuals, CD45RA tended to remain lower on HCV-specific 
CD8+ T cells compared to total CD8+ T cells throughout the entire infection. The subject 
who became chronic upon reinfection also had decreased levels of CD45RA on HCV-
specific T cells. As the combination of CD45RA and CCR7 reveals T cell subsets, 
analysis of these two molecules is extended later.  
An indicator of HCV clearance is elevated expression of the maturation molecule CD127. 
In this study, CD127 usually increased on HCV-specific CD8+ T cells upon clearance of 
virus in subjects who clear reinfection. No changes in CD127 expression upon 
subsequent reinfection in subjects that clear reinfection was observed. Interestingly, 
CD127 expression remained greater on most HCV-specific T cells compared to total CD8 
T cells upon chronic reinfection. However, CD127 expression on HCV-specific T cells 
remained similar to the expression on total CD8 T cells for both chronic infections and 







There appeared to be no uniform pattern of CD28 expression on HCV-specific CD8 T 
cells compared to total CD8 T cells. In one subject who cleared multiple reinfections, 
CD28 levels on HCV-specific T cells were lower compared to total CD8 T cells for all 
but one point during follow-up. However in another subject who cleared multiple 
reinfections, CD28 expression was greater on HCV-specific cells compared to total CD8 
T cells during periods of aviremia. Within each subject, CD28 expression increases upon 
subsequent clearance of reinfection even though the total CD28 expression was lower on 
HCV-specific cells than total CD8 T cells. HCV-specific T cells in during chronic 
reinfection also had increased CD28 expression compared to the primary infection. In 
comparison, the CD28 expression on HCV-specific T cells remained stagnant during 
chronic infection and when the reinfection becomes chronic. Although the CD28 
expression on HCV-specific T cells compared to total CD8 T cells varies between the 
chronic subjects, the level remained the same within each subject's infection. In other 
words, there were only slight to no changes in CD28 expression on HCV-specific T cells 
in chronic infection, but for reinfected subjects the CD28 expression differs depending on 
the presence of virus and upon reinfection outcomes.  
Next, we examined individual molecules of exhaustion on HCV-specific T cells 
compared to total CD8 T cells. In subjects that clear subsequent reinfections, PD-1 
expression was higher on most HCV-specific T cells than total CD8 T cells. The level of 
PD-1 was high after clearance of reinfection, but decreased after extended period of no 
virus. In chronically infected subjects, expression of PD-1 on HCV-specific T cells was 
generally greater than total CD8 T cells. However, there were some exceptions and these 







one chronically infected subject, the PD-1 levels remained higher on HCV-specific cells 
for one epitope, but in the other HCV epitope the PD-1 expression was increased initially 
but then decreased compared to total CD8 T cells. An explanation of this phenomenon is 
that the antigen is no longer intact, as lowered PD-1 levels on virus-specific cells is seen 
during chronic infections (Blattman 2009, Rutebemberwa 2008). Similarly, the subject 
who becomes chronically infected upon reinfection had differences in PD-1 expression 
based on the epitope recognized as shown in Figure 9F. While the HCV-specific T cells 
had higher-than-total CD8 T cell levels of PD-1, one epitope had a much greater 
difference in expression than the other epitope.   
Tim-3 expression tended to be higher on HCV-specific T cells during most aviremic time 
points for reinfected subjects (Figures 9A-C). However, when virus is present, Tim-3 
expression on HCV-specific T cells compared to total CD8 T cells was decreased in 
reinfected subjects. There was no trend upon subsequent infections for Tim-3. In one 
chronic infection, Tim-3 expression on HCV-specific T cells remained similar to total 
CD8 T cell expression and was stagnant throughout infection (Figure 9D). The other 
chronic infection subject was similar to the chronic reinfection subject where Tim-3 
expression is initially the same between the two HCV pentamers studied, but as time 
progressed the Tim-3 expression between the two pentamers in both subjects varied 
greatly (Figure 9E-F). Therefore, in the chronically infected and the chronic reinfection 
subjects who recognize multiple HCV epitopes, there was a different Tim-3 phenotype 
for the different epitopes. Interestingly, as duration of chronic infection increases in both 
the chronically infected and the chronically reinfected subjects, the levels of PD-1 and 







greater Tim-3 expression than total CD8 T cells, the PD-1 expression was lower on 
HCV-specific T cells than total CD8 T cells.  
Finally, we examined differences in activation between reinfected-cleared subjects and 
chronically infected subjects. Within subjects who clear all reinfections, HLA-DR was 
generally elevated on HCV-specific T cells compared to total CD8 T cells when virus 
was detectable. However, HLA-DR was at some time points higher during the period of 
aviremia than during the acute infection and in one instance remained high nearly 800 
days after a reinfection was cleared. In the subject who develops chronic reinfection, 
HLA-DR levels remained elevated on T cells recognizing one HCV epitope but 
decreased on T cells recognizing another HCV epitope. In chronically infected subjects, 
HLA-DR expression on HCV-specific T cells was not consistent between different T cell 
epitopes recognized by the same subject, but generally remained similar to HLA-DR 
expression on the total CD8 T cell population. In one chronic infection, HLA-DR on 
HCV-specific T cells was similar to that on total CD8 T cells but in another subject, 
HLA-DR was elevated to nearly 20 times the level on total CD8 T cells.  
The other activation molecule examined was CD38. Between reinfections, CD38 
decreased during periods of aviremia but increased again once virus was detected. Upon 
subsequent reinfections, CD38 expression did not differ compared to acute infection. 
However, CD38 expression in the subject who developed chronic reinfection never 
decreased during the period of aviremia on the HCV-specific T cells. Additionally, levels 
of CD38 remained elevated on HCV-specific T cells compared to total CD8 T cells in all 







Although CD38 was elevated on HCV-specific T cells during the initial infection in both 
chronic and reinfected subjects, this elevation was only temporary for cleared 
reinfections.  
Dual expressions of molecule subsets on contour plots demonstrate shifting 
populations of HCV-specific T cells over the course of reinfection.  
An advantage of polychromatic flow cytometry is the ability to examine multiple 
molecules on one cell. In this study, we examined dual expression of exhaustion markers, 
activation markers, and classic markers associated with HCV outcome. Representative 
contour plots for dual expression of reinfected subjects and chronically infected subjects 
are in Figure 10A-C and Figure 11A-C respectively. Dual expression of Tim-3 and PD-1 
is a sign of exhaustion. We examined if HCV-specific T cells have similar levels of Tim-
3 and PD-1 upon reinfection as those measured during acute infection. In time points 
when virus was detectable, dual expression of Tim-3 and PD-1 was seen in only one 
subject who cleared reinfection. However, other subjects who cleared multiple 
reinfections expressed one exhaustion marker. Upon reinfection, Tim-3 and PD-1 dual 
expression remained minimal, but most HCV-specific T cells expressed one of the two 
exhaustion markers. In contrast, the majority HCV-specific T cells from chronically 
infected subjects had dual PD-1 and Tim-3 expression during acute infection. 
Interestingly, the proportion of total HCV-specific T cells that have dual expression of 
Tim-3 and PD-1 decreased as infection becomes chronic.  
Activation markers HLA-DR and CD38 on HCV-specific T cells during reinfection were 







throughout the reinfection regardless of presence of virus. Additionally, dual positive 
HLA-DR and CD38 HCV-specific T cells were detected during chronic infection. Due to 
the low number of pentamer+ cells and variation of dual expression of HLA-DR and 
CD38, contour plots do not represent coexpression well so MFI outputs from FlowJo 
were used. Coexpression of CD38 and HLA-DR was elevated not only compared to 
chronic subjects, but this activation status remained similar between reinfections. The 
proportion of HCV-specific T cells that dually express CD38 and HLA-DR from the total 
HCV-specific T cell population in chronically infected subjects were initially elevated 
but decreased over the course of infection. 
Elevated expression of CD127 during acute infection and decreased expression of 
exhaustion marker PD-1 have been correlated with clearance of HCV infection in 
previous studies (Golden-Mason 2006, Rutebemberwa 2008). To determine whether this 
was true with reinfection, we examined dual expression on HCV-specific T cells. HCV-
specific T cells in reinfected subjects maintained high levels of CD127, but PD-1 
decreased as duration from viral clearance increased. In comparison, HCV-specific T 
cells from chronically infected subjects did not dually express CD127 and PD-1 but had a 
greater proportion of CD127-/PD-1+ T cells throughout the infection.  
Examination of T cell subsets using CCR7 and CD45RA revealed no great differences 
between reinfections of the same subject with representative classifications shown in 
Figure 13. Upon initial viremia during a reinfection, there was a spike in HCV-specific 
effector memory T cell population, followed by an increase in central memory T cell 







naïve T cells dominated but there was also a high percent of central memory T cells even 
in the presence of virus. Interestingly, as the reinfection becomes chronic, the effector 
memory T cell population became the least represented T-cell subset. In subjects who 
developed chronic infection, most HCV-specific T cells were naïve followed by either 
central memory T cells or effector memory T cells, and then Temra as the least 
represented. In contrast, HCV-specific T cells from reinfected subjects fluctuate between 



















Figure 8. Representative gating to HCV-specific CD8 T cells 
Cells were first gated on lymphocytes using side scatter (SSC)-area and forward scatter 
(FSC)-area. Single cells were gating using FSC-height and FSC-width. Doublets have 
double the width value while maintaining the same height. Stricter single cells gating was 
used with SSC-height and SSC-width. Live cells were gated using SSC-height against the 
AmCyan Aquaviability Live/Dead dye. CD8+ T cells were gating based on CD4 (PE-
CF594) and CD8 (Alexa Fluor 700). Pentamer+ cells were gated using Pentamer (APC) 












Figure 9A-F. Individual MFI for each surface marker for each subject with virus 
levels. Each dot denotes the ratio of MFI from pentamer+ to the total CD8 T cells. 
The different colors of the dots indicate different HCV epitopes recognized. Any dot 
above the line indicates HCV-specific T cells that have higher MFI than total CD8+ 
T cell population. Vertical lines indicate reinfection and clearance of virus for 
reinfected subjects. For chronic subjects (Figure 9D and 9E), vertical lines are for 
































































          Initial Infection      First Reinfection   
          224/+       586/+       1037/-       1168/-               21/+           38/+         112/- 
 
 
         Second Infection                              Third Reinfection 
         15/+           58/-        737/-                  57/-         122/- 
 
          Fourth Reinfection 
          20/+         90/-          176/-    
 
Figure 10A. Representative double positive contour plots of Tim-3 versus PD-1 in 
subject 112 who cleared four reinfections. The top row in each set is HCV-specific T 
cells while the bottom row is all CD8+ T cells from the same time point. The 
numbers below the infection label indicate the number of days after virus detected 
for either the initial infection or the respective reinfection. The +/- indicates whether 
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Figure 10B. Representative double positive contour plots of HLA-DR versus CD38  
in subject 112 who cleared four reinfections. Each new axes label indicates a new 
reinfection. The top row in each set is HCV-specific T cells while the bottom row is 
all CD8+ T cells from the same time point. The numbers below the infection label 
indicate the number of days after virus detected for either the initial infection or the 
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Figure 10C. Representative double positive contour plots of CD127 versus PD-1 in 
subject 112 who cleared four reinfections. Each new axes label indicates a new 
reinfection. The top row in each set is HCV-specific T cells while the bottom row is 
all CD8+ T cells from the same time point. The numbers below the infection label 
indicate the number of days after virus detected for either the initial infection or the 









Figure 11A-C. Representative double positive contour plots of Tim-3 versus PD-1 in 
subject 30 who is chronically infected. The top row is HCV-specific T cells while the 
bottom row is all CD8+ T cells from the same time point. The diagrams are oriented 
so that time from initial infection is increasing. The arrows indicate where along the 









Figure 11B. Representative double positive contour plots of HLA-DR versus CD38 









Figure 11C. Representative double positive contour plots of CD127 versus PD-1 in 











Figure 12A-C. Representative HCV-specific T cell subset population analysis for 
subject 176 who clears multipe reinfections. Blue lines indicate effector memory T 
cells (CCR7-/CD45RA-), red lines indicate Temra cells (CCR7-/CD45RA+), green 
lines indicate naïve T cells (CCR7+/CD45RA+), and purple lines indicate central 
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Figure 12B. Representative HCV-specific T cell subset population analysis for 
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Figure 12C. Representative HCV-specific T cell subset population analysis for a 
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As examined in earlier studies, the magnitude of the T cell response increased upon 
reinfection. However, there was no significant difference in the breadth of the CD8 T cell 
response comparing primary infection and first reinfection. Interestingly, there was a 
significant difference in the breadth of response at the latest time point available 
compared to the primary infection. Even upon continued exposure resulting in infection, 
there is a memory component enabling rapid viral clearance characterized by increased 
breadth and increased magnitude of response that continues to increase upon subsequent 
reinfections.  
Successful control of other infection is associated in some cases with recognition of 
specific T cell epitopes, known as immunodominance. Although new epitopes are 
recognized upon reinfection, with HCV, there is no immunodominance. Additionally, 
within subjects the dominance of epitopes recognized shifts between reinfections. This 
suggests that there is no specific region along the HCV polyprotein that is recognized by 
subjects able to clear reinfection. Conversely, there is no dominant region along the HCV 
polyprotein that is recognized by subjects unable to clear reinfection.  
In examining individual molecule expression on HCV-specific T cells compared to total 
CD8+ T cells in reinfected subjects, there were no pronounced differences in expression 
between reinfections and the initial infection. Interestingly, CCR7, PD-1, and Tim-3 
varied within subjects depending on the specific HCV epitope targeted. This could 







HCV-specific T cells in reinfections remained activated, as demonstrated by 
coexpression of HLA-DR and CD38 throughout follow-up regardless of the presence of 
virus. In contrast, dual-expressing activated HCV-specific T cells in chronically infected 
subjects were present initially at high levels relative to the general CD8 T cell population, 
but decreased over the course of the infection. This could be due to a viral escape 
mutation of recognized epitopes. Unfortunately viral evolution analysis was not 
performed in this study at every time point across all epitopes so this remains to be 
determined.  
Analysis of T cell subsets in this study provided curious information regarding the 
percent of naïve T cells. In both chronically infected subjects and reinfected subjects, the 
naïve T cell population usually dominated the HCV-specific T cell population. 
Instrument set-up, voltages, and FMO gating were thoroughly analyzed to ensure that 
these were not the cause of a high percentage of naïve T cell subsets. The subsets of 
naïve, effector memory, central memory, and Temra HCV-specific T cells varied 
between reinfections and presence of virus as expected. However, in chronic infection, 
Temras become least represented among HCV-specific CD8 T cells.  
In order to comprehensively grasp the cellular immune response, future studies need to 
performed. First, assessing the function of HCV-specific T cells would be beneficial to 
determine antiviral potential. Therefore, intracellular cytokine staining of HCV-specific T 
cells is planned. Additionally, deep sequencing of HCV epitopes would be useful and 
would determine if the antigen is intact at the time points tested. A change in phenotype 







viral escape of that epitope with no T cell engagement. Finally, more subjects need to be 
analyzed. Although there are multiple reinfections in the BBAASH study, cellular 
analysis is limited. Increasing the number of reinfections will increase the power of 
analysis.  
There are many variables in this study that could affect outcome such as sampling time, 
subject characteristics, genotype of infection, T cell epitopes recognized, and even 
duration of cell storage in the liquid nitrogen freezers. Although some variables can be 
controlled, such as subject study characteristics, other variables cannot be, such as time 
storage in the liquid nitrogen freezers. Additionally, it is important to remember that 
many arms of the immune system work together to fight viral pathogens. In this study, 
we examined only CD8 T cells, but CD4 T cells, antibodies, and the innate immune 
recognition could all be potential factors in clearing HCV.  
CONCLUSION 
Epitope recognition analysis revealed that reinfections continue to maintain a robust 
immune response measured by magnitude and breadth of response. Although no 
dominant phenotype was noted among subjects who clear multiple reinfections, HCV-
specific T cells fluctuate activation and exhaustion molecule expression, indicating that 
the T cell response is not static, but rather evolving continuously upon reinfection. 
Importantly, further studies need to be performed to determine the function of these 
HCV-specific T cells. However, the results from this study suggest that subjects able to 
clear multiple reinfections have HCV-specific CD8 T cells capable of increasingly robust 
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